Abstract
International guidelines recommend multigene germline (MGP) testing for PC pts, although no surveillance program for high-risk individuals has been validated. The implementation of this recommendation is limited by the uncertainty around its clinical utility. Preliminary data from Italian PC pts showed a high prevalence of CDKN2A PV, regardless of familial status, and BRCA1/2 PVs only in pts<74 yo. Here, we provide a comprehensive analysis by MGP in unselected Italian PC pts.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
